The role of mutation in the new cancer paradigm

Cancer Cell International

Volumn 5, Issue , 2005, Pages

  Prehn, Richmond T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer regression; Carcinogenesis; Cloning; Differentiation; Epigenetic; Mutation

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CARCINOGEN; MYC PROTEIN; TRANSCRIPTION FACTOR OTX2; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BRAIN DEVELOPMENT; CANCER GENETICS; CANCER INCIDENCE; CANCER REGRESSION; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; CHROMOSOME ABERRATION; CLONAL VARIATION; DNA REPAIR; EMBRYO DEVELOPMENT; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; MALIGNANT TRANSFORMATION; MUTAGENESIS; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; SKIN CANCER;

EID: 26844555296     PISSN: 14752867     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-5-9     Document Type: Article

References (42)

1. Soto A, Sonnenschein C: The somatic mutation theory of cancer: growing problems with the paradigm? BioEssays 2004, 26:1097-1107.
2. Loeb LA: A mutator phenotype in cancer. Cancer Res 2001, 61:3230-3239.
3. Tanooka H, Tanaka K: Dose response of monoclonal tumor induction with 3-methylcholanthrene in mosaic mice. Cancer Res 1984, 44:4630-4632.
4. Venema J, van Hoffen A, Karcagi V, van Hoffen A, Natarajan AT, van Zeeland AA, Mullenders LHF: Xeroderma complementation group C cells remove pyrimidine dimers selectively from the transcribed strand of active genes. Mol Cell Biol 1991, 11:4128-34.
5. Farber E, Rubin H: Cellular adaptation in the origin and development of cancer. Cancer Res 1991, 51:2751-2761.
6. Rubin H: Spontaneous transformation as aberrant epigenesis. Differentiation 1993, 53:123-137.
7. Pierce GB, Speers WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directed differentiation. Cancer Res 1988, 48:1996-2004.
8. Jaffe LF: Epigenetic theories of cancer initiation. Adv Cancer Res 2003, 90:209-230.
9. Prehn RT: Cancers beget mutations versus mutations beget cancers. Cancer Res 1994, 54:5296-5300.
10. Ashby J, Tennant RW: Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U. S. NCI/NTP. Mutat Res 1988, 204:17-115.
11. Luch A: Nature and nurture- lessons from chemical carcinogenesis. Nat Rev Cancer 2005, 5:113-125.
12. Bates RR, Klein M: The importance of a smooth surface in carcinogenesis by plastic film. J Natl Cancer Inst 1966, 37:145-151.
13. Pikarsky E, Porat RM, Stein H, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-6.
14. Beachy PA, Karhadkar SS, Berman DM: Mending and malignancy. Nature 2004, 431:402. (only)
15. Maffini MV, Soto MA, Calabrol JM, Angelo AU, Sonnenschein C: The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004, 117:1495-1502.
16. Mondal S, Heidelberger C: In vitro malignant transformation by methylcholanthrene of the progeny of single cells derived from C3H mouse prostate. Proc Natl Acad Sci USA 1970, 65:219-25.
17. Alfred LJ, Globerson A, Berwald Y, Prehn RT: Differential toxicity response of normal and neoplastic cells to 3,4-benzopyrene and 3-methylcholanthrene. Br J Cancer 1964, 18:159-64.
18. Vasiliev JuM, Guelstein VI, Starikova B, Yagorskaya TA: Differential sensibility of normal and tumour cells in two mouse tissues to the toxic activity of cancerogenic substances belonging to various chemical classes. Neoplasma 1957, 14:35-39.
19. Haas D, Ablin AR, Miller C, et al.: Complete morphologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 1988, 62:818-25.
20. Andrews EJ: Evidence of the nonimmune regression of chemically induced tumors in mouse skin. J Natl Cancer Inst 1971, 47:653-65.
21. Reddy AL, Caldwell M, Fialkow PJ: Studies of skin tumorigenesis in PGK mosaic mice: many promoter-independent papillomas and carcinomas do not develop from pre-existing promoter-dependent papillomas. Int J Cancer 1987, 39:261-5.
22. Brinster RL: The effect of cells transferred into the mouse blastocyst on subsequent development. J Exp Med 1974, 140:1049-56.
23. Illmensee K, Mintz B: Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 1976, 73:549-53.
24. McCullough K, Coleman W, Ricketts S, Wilson JW, Smith GJ, Grisham JW: Plasticity of the neoplastic phenotype in vivo is regulated by epigenetic factors. Proc Natl Acad Sci USA 1998, 95:15333-8.
25. Gerschenson M, Graves K, Carson SD, Wells RS, Pierce GB: Regulation of melanoma by embryonic skin. Proc Natl Acad Sci USA 1986, 83:7307-19.
26. Hochedlinger K, Blelloch R, Brennan C, Yamada Y, Kim M, Chin L, Jaenisch R: Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004, 18:1875-85.
27. Sporn MB: Carcinogenesis and cancer-different perspectives on the same disease. Cancer Res 1991, 51:6215-8.
28. Kenny PA, Bissell MJ: Tumor reversion: correction of malignant behavior by microenvironmental cues. Int J Cancer 2003, 107:688-95.
29. Knudson AG: A personal sixty-year tour of genetics and medicine. Annu Rev Genomics Hum Genet 2005 in press.
30. Di C, Lio S, Adamson DC, Parrot TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, McLendon RE, Bigner DD, Yan H: Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005, 65:919-24.
31. Shachaf CM, Kopelman AM, Aranitis C, Karisson CA, Beer S, Mandi S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-7.
32. Rowley JD: Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001, 1:245-50.
33. Mellon I, Bohr VA, Smith CA, Hanawalt PC: Preferential DNA repair of an active gene in human cells. Proc Natl Acad Sci USA 1986, 83:8878-82.
34. Bielas JH, Meddle JA: Proliferation is necessary for both repair and mutation in transgenic mouse cells. Proc Natl Acad Sci USA 2000, 97:11391-11396.
35. Mirsalis JC, Shimon JA, Johnson A, Fairchild D, Kanazawa N, Nguyen T, de Boer J, Glickman B, Winegar RA: Evaluation of mutant frequencies of chemically induced tumors and normal tissues in l/cll transgenic mice. Environmental and Molecular Mutagenesis 2005, 45:17-35.
36. Zuckerman NJ, Nardella P, Morris HP, Elwood JC: Lack of adaptation in lipogenesis by Morris hepatomas 9098, 7794A and 9618A. J Natl Cancer Inst 1970, 44:79-83.
37. Potter VR, Watanabe M, Pitot HC, Morris HP: Systematic oscillations in metabolic activity in rat liver and hepatomas. Survey of normal diploid and other hepatoma lines. Cancer Res 1969, 29:55-78.
38. Chieco-Bianchi I, De Benedictis G, Tridente G, Fiore-Donati L: Influence of age on susceptibility to liver carcinogenesis and skin initiating action by urethane in Swiss mice. Br J Ca 1963, 17:672-80.
39. McKinnell RG, Deggins BA, Labat DD: Transplantation of pluripotent nuclei from triploid frog tumors. Science 1969, 165:394-6.
40. Reddy AL, Fialkow PJ: Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methycholanthrene. J Exp Med 1979, 150:878-87.
41. Reddy AL, Fialkow PJ: Probable clonal development of foreign-body-induced murine sarcomas. J Natl Cancer Inst 1984, 72:467-70.
42. Reddy AL, Fialkow PJ: Papillomas induced by initiation- promotion differ from those induced by carcinogen alone. Nature 1983, 304:69-71.